Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Acquisition

Gujarat Themis Biosyn Acquisition Worth ₹1,722 Cr

Gujarat Themis Biosyn Limited has agreed to acquire 13 anti-tuberculosis and anti-infective brands from Sanofi for ₹1,722.2 Crore (Euro 158 million). The acquisition provides immediate access to regulated markets in Europe, Middle East, and Africa. The transaction is expected to close by December 2026, strengthening GTBL's global generic pharmaceuticals platform.

Key figures
Value₹1,722 Cr
Execution periodBy end of December 2026
Source

BSE filing, NSE: GUJTHEM. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Gujarat Themis Biosyn Ltd: key numbers

Share price
₹355.55
Market cap
₹4,628 Cr
Revenue (annual)
₹165.8 Cr
Net profit (annual)
₹46.68 Cr
P/E (TTM)
95.0×Sector 46.1×
Promoter holding
59.33%-11.53% QoQ
FII holding
3.80%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Gujarat Themis Biosyn Ltd

All →

Other acquisition announcements

All →